1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - For individual participant data meta-analysis.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [niraj.gopinath@smsimsr.org].
   


6. For how long will this data be available start date provided 02-08-2027 and end date provided 01-08-2030?
   Response - Beginning 9 months and ending 36 months following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

 Osteoarthritis of the knee (OAK) can cause significant pain, dysfunction, distress and impaired quality of life affecting 3.3% of the worldwide population¹. OAK is not just a disease of the cartilage. Pain generators in OAK are present in both intra and extra articular structures^{2 ,3}. Initial management includes analgesic medications and physiotherapy. Patients who fail to respond have two major options that include intra-articular treatments and total knee replacement (TKR)^4-7. TKR is a major and expensive undertaking. There is a 10-20% chance of persistent knee pain after TKR^{8, 9}. Various intra-articular treatments have been trialed with an objective of providing pain relief, improving function and avoiding or delaying TKR. These include intra-articular corticosteroid (IACS), intra-articular platelet rich plasma (PRP) therapy, intra-articular hyaluronidase, hypertonic dextrose prolotherapy (HDP) and Ozone therapy^{4-7, 10-12}. Hyaluronic acid is not recommended for routine use in the treatment of symptomatic OAK⁴.  IACS injection is the recommended standard treatment⁴. However, there is a potential for chondrotoxic and osteoporotic side effects⁵. PRP therapy requires specialized equipment and theatre setting to avoid infection (septic arthritis)⁶. Intra-articular ozone therapy has a good safety profile^{11, 12}. However, analgesia beyond 6 months is questionable¹². 

Corticosteroid, PRP or Hyaluronidase target the intra articular pain generator while ignoring the extra-articular structures like ligaments and muscles. HDP involves peri-articular injections that targets intra and extra articular pain generators, is cost effective, has an excellent safety profile with potential regenerative benefits^{14, 15}. However, it provides short-term benefit in OAK^14-16.

Intra articular magnesium (IAM) has significant analgesic benefits following knee arthroscopy¹⁷. There is experimental evidence that IAM prevents progression of OAK¹⁸. 

There have been no studies till date that has compared the effectiveness of combined Dextrose Magnesium Ozone (DMO) Therapy with corticosteroid Therapy. Our hypothesis is that by combining the regenerative, analgesic and immunomodulating properties of Hypertonic Dextrose, Ozone and Magnesium, durable analgesia and improved function can be provided at a low cost. The present study assesses analgesic efficacy of Dextrose Magnesium Ozone (DMO) Therapy when compared to IACS.